Minor QS Infractions Will Not Add Up To FDA Warning Letter
This article was originally published in The Silver Sheet
Executive Summary
"MINOR" QUALITY SYSTEM NONCONFORMITES uncovered during inspections will not trigger follow-up regulatory action under FDA's final revised medical device compliance program guide. Industry had argued that too many warning letters would result from the agency's draft plan to count numerous minor QS deviations as the basis for an "Official Action Indicated" inspection designation. The number of device QS warning letters issued by FDA in 1999 dropped by 18% compared to the 1998 total. Process validation and complaint-handling infractions continue to be prevalent as industry prepares for the agency's new quality systems inspection technique. WARNING LETTERS: Abbott Labs cited for QS reg deficiencies in the manufacture of Alcyon clinical chemistry analyzers; Sulzer BAK promotions contain "inappropriate" comparisons to Sofamor Danek device, FDA says
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.